Health & Biotech
Health: Admedus shares fly 40pc on first trading day in six months
Dr Boreham’s Crucible: Recce Pharmaceuticals, the emerging superbug killer
Health: Oncosil stays hopeful with regulators, shares move higher
‘People want revenues and a genuine business’: how ASX pot stocks are maturing
Orthocell’s technology might have helped cure Superman
Clinuvel on top of the world after FDA approval caps off rise of 4000%
Weed Week: Australia’s cannabis legalisation is all over the joint
The Health Kick Podcast with Tim Boreham: Kazia Therapeutics
Clinuvel surges to all-time high on US green light
Health: Zelda wants to buy a private US-based medicinal cannabis company
Biotech: With Phase II trials underway, Dimerix eyes first-mover advantage in the US market
These are the three biggest opportunities for digital transformation in pharma
Brain apps hit their stride as deals start to flow
Dr Boreham’s Crucible: Actinogen on the mend after a near-death experience
Health: Joining a German startup accelerator sends ResApp to two-year high
Eye health is a growing, multi-billion-dollar market. Which stocks are worth a look?
MGC Pharma growth accelerates as prescription sales double in two weeks
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
